07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

Recombinant human nerve growth factor: Phase Ib/II started

Dompe began the 24-week, double-blind, vehicle-controlled, Italian Phase Ib/II Lumos trial to evaluate 60 and 180 µg/mL rhNGF eye drops in about 50 patients. The product is also in the Phase I/II REPARO trial to...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Recombinant human nerve growth factor regulatory update

Dompe said FDA granted Orphan Drug designation for rhNGF eye drop solution to treat retinitis pigmentosa. The recombinant human nerve growth factor has Orphan Drug designation in the EU for the indication. The product is...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

rhNGF recombinant human nerve growth factor regulatory update

Dompe said the European Commission granted Orphan Drug designation for its rhNGF to treat retinitis pigmentosa. The product is in the Phase I/II REPARO trial to treat neurotrophic keratitis. Dompe gained rights to the product...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

Anabasis, Dompe SpA deal

Dompe will acquire the 51% of partner Anabasis it does not already own for an undisclosed amount, including an upfront payment and milestones related to Anabasis' ophthalmic formulation of nerve growth factor (NGF) . Dompe,...
02:16 , Feb 28, 2012 |  BC Extra  |  Company News

Dompe to acquire Anabasis

Dompe SpA (Milan, Italy) will acquire the 51% of partner Anabasis s.r.l. (Milan, Italy) it does not already own for an undisclosed amount, including an upfront payment and milestones related to Anabasis' ophthalmic formulation of...
08:00 , Jan 2, 2012 |  BioCentury  |  Emerging Company Profile

Anabasis: Eyeing NGF

Anabasis s.r.l . is developing an ophthalmic formulation of nerve growth factor , which could become the first disease-modifying treatment for neurotrophic keratitis, dry eye and glaucoma. Nerve growth factor (NGF) is a secreted protein...